

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., DR. REDDY'S
LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD., SUN
PHARMACEUTICAL INDUSTRIES LTD., AND SUN
PHARMACEUTICAL INDUSTRIES, INC.,
Petitioner,

v.

NOVO NORDISK A/S,
Patent Owner.

IPR2023-00724¹
Patent 10,335,462 B2

REVISED SCHEDULING ORDER

¹ IPR2024-00009 (Dr. Reddy's Laboratories) and IPR2024-00107 (Sun Pharmaceutical Industries) have been joined with this proceeding.

Novo Nordisk, A/S, requested a conference call to discuss a one-month extension of all due dates, including the oral hearing date, to accommodate the scheduling of depositions of Petitioner's six declarants that filed declarations in support of Petitioner's Reply. *See Ex. 3004.* Petitioner did not take a position on Patent Owner's request. *Id.*

A conference call was held on June 6, 2024, to discuss the proposed changes to the schedule for this proceeding. During the conference, we authorized the parties to file a joint stipulation concerning the proposed due dates for Due Dates 3 through 7, but took under advisement the change in the oral hearing due date to confirm availability for an oral hearing during the week of August 26, 2024. Counsel confirmed that each would be available for an oral hearing during that week.

On June 7, 2024, the parties filed a joint stipulation to modify Due Dates 3 through 7 as follows (omitting events related to a motion to amend that Patent Owner has agreed not to file in this proceeding). *See Paper 56, 1, 1 n.1 ("Joint Stipulation").*

Due Date	Current Date	Proposed Due Date
DUE DATE 3: Patent Owner's sur-reply to reply	July 3, 2024	August 5, 2024
DUE DATE 4: Request for oral argument	June 12, 2024	July 12, 2024
DUE DATE 5: Motion to exclude evidence	July 8, 2024	August 8, 2024
DUE DATE 6: Opposition to motion to exclude and Request for prehearing conference	July 15, 2024	August 15, 2024
DUE DATE 7: Reply to opposition to motion to exclude	July 18, 2024	August 19, 2024
DUE DATE 8: Oral argument	July 30, 2024	To be specified by the Board

IPR2023-00724
Patent 10,335,462 B2

We have since confirmed the *morning of Tuesday, August 27, 2024*, as the date and time for oral argument should it be requested by the parties. We have confirmed that a requested in-person hearing will be held at the USPTO headquarters in Alexandria in our largest courtroom, Hearing Room A.

ORDER

Accordingly, it is

ORDERED that DUE DATE 8 for Oral Argument is set for the *morning of Tuesday, August 27, 2024*;

FURTHER ORDERED that the the due dates set forth in the Joint Stipulation by the parties filed for Due Dates 3 through 7 filed on June 7, 2024, remain in effect.

IPR2023-00724
Patent 10,335,462 B2

For PETITIONER:

Brandon M. White
Emily J. Greb
Courtney Prochnow
Christopher D. Jones
Jonathan I. Tietz
Matthew A. Lembo
PERKINS COIE LLP
white-ptab@perkinscoie.com
greb-ptab@perkinscoie.com
prochnow-ptab@perkinscoie.com
jones-ptab@perkinscoie.com
tietz-ptab@perkinscoie.com
lembo-ptab@perkinscoie.com
Semaglutide-Ozempic@perkinscoie.com

For PATENT OWNER:

J. Steven Baughman
Megan Raymond
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
steve.baughman@groombridgewu.com
megan.raymond@groombridgewu.com